A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin Angiotensin Aldosterone System Inhibitor (RAASi) Medications for the Treatment of Heart Failure (DIAMOND)
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Patiromer (Primary)
- Indications Hyperkalaemia
- Focus Registrational; Therapeutic Use
- Acronyms DIAMOND
- Sponsors Relypsa; Vifor Pharma
Most Recent Events
- 08 Mar 2024 This trial has been completed in Italy according to European Clinical Trials Database record.
- 01 Dec 2022 This trial has been completed in Poland, according to European Clinical Trials Database (2 Sep 2021).
- 28 Jul 2022 Results published in the European Heart Journal